126 related articles for article (PubMed ID: 22781384)
1. Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data.
Gwak HS; Lim HS; Shin SH; Yoo H; Han JY; Kim HT; Yun T; Lee JS; Lee SH
Am J Clin Oncol; 2013 Oct; 36(5):491-9. PubMed ID: 22781384
[TBL] [Abstract][Full Text] [Related]
2. Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study.
Gwak HS; Joo J; Shin SH; Yoo H; Han JY; Kim HT; Yun T; Ro J; Lee JS; Lee SH
Oncologist; 2014 Oct; 19(10):1044-5. PubMed ID: 25209375
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of slow-rate ventriculolumbar perfusion chemotherapy for leptomeningeal carcinomatosis: a phase II study.
Jang S; Gwak HS; Joo J; Doh YS; Shin SH; Yoo H; Wang KC
Acta Neurochir (Wien); 2024 Mar; 166(1):117. PubMed ID: 38424255
[TBL] [Abstract][Full Text] [Related]
5. An open-label phase I pilot study of continuous intrapleural infusion of escalated doses of methotrexate in malignant pleural mesothelioma.
Ellithy MM; El Baghdady NS; El Wakeel LM; Abdeltawab KA; Badary OA
Am J Clin Oncol; 2013 Oct; 36(5):514-8. PubMed ID: 22781392
[TBL] [Abstract][Full Text] [Related]
6. [Intrathecal methotrexate chemotherapy for leptomeningeal carcinomatosis].
Kullmann T; Gauthier H; le Maignan C; Szabó A; Culine S
Orv Hetil; 2012 Sep; 153(35):1385-8. PubMed ID: 22935431
[TBL] [Abstract][Full Text] [Related]
7. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.
Fizazi K; Asselain B; Vincent-Salomon A; Jouve M; Dieras V; Palangie T; Beuzeboc P; Dorval T; Pouillart P
Cancer; 1996 Apr; 77(7):1315-23. PubMed ID: 8608509
[TBL] [Abstract][Full Text] [Related]
8. Ventriculolumbar perfusion chemotherapy with methotrexate and cytosine arabinoside for meningeal carcinomatosis: a pilot study in 13 patients.
Nakagawa H; Fujita T; Kubo S; Izumoto S; Nakajima Y; Tsuruzono K; Tokiyoshi K; Hayakawa T
Surg Neurol; 1996 Mar; 45(3):256-64. PubMed ID: 8638223
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and Security of Intrathecal with Methotrexate in the Treatment of Meningeal Carcinomatosis].
Wu X; Li J; Xiao J; Yang B; Yu L; Wu X; Wan J; Xu H; Kong J
Zhongguo Fei Ai Za Zhi; 2016 May; 19(5):252-6. PubMed ID: 27215452
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic monitoring of 24-hour infusion of methotrexate in an adult population with non-Hodgkin lymphoma].
Fernández Megía MJ; Alós Almiñana M; Esquer Borrás J
Farm Hosp; 2004; 28(6):433-9. PubMed ID: 15628946
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of leptomeningeal carcinomatosis from gastric cancer].
Okuda T; Kataoka K; Kato A
Gan To Kagaku Ryoho; 2009 Apr; 36(4):599-603. PubMed ID: 19381031
[TBL] [Abstract][Full Text] [Related]
12. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis.
Tetef ML; Margolin KA; Doroshow JH; Akman S; Leong LA; Morgan RJ; Raschko JW; Slatkin N; Somlo G; Longmate JA; Carroll MI; Newman EM
Cancer Chemother Pharmacol; 2000; 46(1):19-26. PubMed ID: 10912573
[TBL] [Abstract][Full Text] [Related]
14. [Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan].
Nakagawa H; Tamura M; Fukushima Y; Majima S; Yamada K
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1799-805. PubMed ID: 18030013
[TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
16. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
17. [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
Cochereau D; Da Costa S; Le Maignan C; Gauthier H; Cochereau J; Espié M; Giacchetti S; Teixeira L
Bull Cancer; 2016 May; 103(5):444-54. PubMed ID: 26987841
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience.
Garrett AP; Garner EO; Goldstein DP; Berkowitz RS
J Reprod Med; 2002 May; 47(5):355-62. PubMed ID: 12063874
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of methotrexate in systemic tissues after intrathecal administration.
Bleyer WA; Nelson JA; Kamen BA
J Pediatr Hematol Oncol; 1997; 19(6):530-2. PubMed ID: 9407940
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
